ScholarLens Back to search
2007•Chinese Journal of Modern Drug ApplicationRequires access

Clinical study of FOLFOX4 plus thalidomide in the treatment of advanced intestinal cancers

Liangmin Zhang

Open publisher page 0 citations

Abstract

Objective To observe the therapeutic effects and adverse effect,which consists of thalidomide combined with biweekly regimen of leucovorin,5-fluorouracil and oxaliplatin(FOLFOX4)in treatment of advanced intestinal cancers.Methods 38 patients with advanced intestinal cancers received thalidomide(200 mg/d,d1-10),chemotherapy of regimen L-OHP 85 mg/m2 2 hours iv on day1,CF200 mg/m2 2 hours iv on day 1 to 2,followed by 5-FU400 mg/m2 iv and 600 mg/m2 22 hours on day 1 to 2,two weeks as one circle.Efficacy was evaluated after 4 circles.Results Four patients achieved complete response(CR),17 patients partial response(PR),11 patients stable disease(SD),6 patients progression disease(PD).Overal response rate was 55.26%.The major toxicity include neurosensory,nausea,vomiting,leucopenia.Conclusion This study shows that the regimen of thalidomide combined FOLFOX4 is effective and tolerable in advanced intestinal cancers.

About this research paper

What this paper is about

Objective To observe the therapeutic effects and adverse effect,which consists of thalidomide combined with biweekly regimen of leucovorin,5-fluorouracil and oxaliplatin(FOLFOX4)in treatment of advanced intestinal cancers.Methods 38 patients with advanced intestinal cancers received thalidomide(200 mg/d,d1-10),chemotherapy of regimen L-OHP 85 mg/m2 2 hours iv on day1,CF200 mg/m2 2 hours iv on day 1 to 2,followed by 5-FU400 mg/m2 iv and 600 mg/m2 22 hours on day 1 to 2,two weeks as one circle.Efficacy was evaluated after 4 circles.Results Four patients achieved complete response(CR),17 patients partial response(PR),11 patients stable disease(SD),6 patients progression disease(PD).Overal response rate was 55.26%.The major toxicity include neurosensory,nausea,vomiting,leucopenia.Conclusion This study shows that the regimen of thalidomide combined FOLFOX4 is effective and tolerable in advanced intestinal cancers.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the therapeutic effects and adverse effect,which consists of thalidomide combined with biweekly regimen of leucovorin,5-fluorouracil and oxaliplatin(FOLFOX4)in treatment of advanced intestinal cancers.Methods 38 patients with advanced intestinal cancers received thalidomide(200 mg/d,d1-10),chemotherapy of regimen L-OHP 85 mg/m2 2 hours iv on day1,CF200 mg/m2 2 hours iv on day 1 to 2,followed by 5-FU400 mg/m2 iv and 600 mg/m2 22 hours on day 1 to 2,two weeks as one circle.Efficacy was evaluated after 4 circles.Results Four patients achieved complete response(CR),17 patients partial response(PR),11 patients stable disease(SD),6 patients progression disease(PD).Overal response rate was 55.26%.The major toxicity include neurosensory,nausea,vomiting,leucopenia.Conclusion This study shows that the regimen of thalidomide combined FOLFOX4 is effective and tolerable in advanced intestinal cancers.

Key concepts: Thalidomide, Oxaliplatin, Regimen, Medicine, Gastroenterology, Vomiting, Nausea, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of FOLFOX4 plus thalidomide in the treatment of advanced intestinal cancers — Research Paper | ScholarLens